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Abstract: Psoriasis is associated to an increased risk of cardiovascular (CV) complications. 
Overall, the pathogenic mechanisms involved in premature CV complications in psoriasis 
appear to be complex and multifactorial, with traditional and nontraditional risk factors possibly 
contributing to the increased risk. Based on what is known about the pathogenesis of psoriasis 
and extrapolating the current knowledge on CV complications in other inﬂ  ammatory diseases, 
studies are needed to investigate if appropriate control of the inﬂ  ammatory, immunologic and 
metabolic disturbances present in psoriasis can prevent the development of this potentially lethal 
complication. It is clear that there is a great need for heightened awareness of the increased 
risk for vascular damage in patients with psoriasis. It is also crucial to closely monitor patients 
with psoriasis for CV risk factors including obesity, hypertension, diabetes, and hyperlipidemia. 
Whether treatment regimens that effectively manage systemic inﬂ  ammation will lead to 
prevention of CV complications in psoriasis needs to be investigated. Clearly, studies should 
focus on establishing the exact mechanisms that determine CV risk in psoriasis so that appropriate 
preventive strategies and treatment guidelines can be established.
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Psoriasis and cardiovascular (CV) disease
Psoriasis is a chronic inﬂ  ammatory disorder with an estimated prevalence in the US 
of 2.2% in individuals 18 years old and older (Gelfand et al 2005). According to 
the National Institutes of Health in the US, between 5.8 and 7.5 million Americans 
have psoriasis. Approximately 6%–11% of patients with psoriasis have an associated 
inﬂ  ammatory arthropathy (psoriatic arthritis, PsA). Psoriasis and PsA are characterized 
by cycles of remission and exacerbation and signiﬁ  cantly affect quality of life by 
causing signiﬁ  cant morbidity. Indeed, the impact of psoriasis on health-related quality 
of life is similar to that of other major medical diseases, including cancer, hypertension 
and diabetes (Rapp et al 1999).
Similar to other inﬂ  ammatory disorders, psoriasis is not conﬁ  ned to the skin but, 
rather, considered a systemic inﬂ  ammatory condition. This is indicated by several 
observations, including the presence of elevated inﬂ  ammatory markers in serum 
of patients with psoriasis (Rocha-Pereira et al 2004); the development of articular 
involvement, and the association with the metabolic syndrome (Azfar and Gelfand 
2008). Several factors, including genetic determinants, ethnic and regional variations 
have been associated with disease pathogenesis and with ﬂ  ares of symptomatology 
(see pathogenesis section below).
Recent evidence indicates that immunological abnormalities in patients with 
psoriasis may predispose them to an increased risk of other diseases with an 
inﬂ  ammatory basis, including atherosclerosis and premature vascular damage. 
As such, similar to other systemic autoimmune/proinﬂ  ammatory conditions such 
as rheumatoid arthritis (RA) (Kaplan, 2006) and systemic lupus erythematosus Vascular Health and Risk Management 2008:4(6) 1230
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(SLE) (Rajagopalan et al 2004), psoriasis is associated 
with an increased CV risk. Indeed, the prevalence and 
severity of coronary artery calciﬁ  cation is signiﬁ  cantly 
higher in patients with psoriasis (Ludwig et al 2007), and 
several epidemiologic studies have described an associa-
tion between psoriasis and coronary events, as well as to 
well-known risk factors of coronary artery disease (CAD) 
(Gelfand et al 2006; Neimann et al 2006; Shapiro et al 
2007; Ludwig et al 2007; Kimball et al 2008). Patients 
with psoriasis have an increased adjusted relative risk 
for myocardial infarction (MI) that varies by age. For a 
30-year-old patient with mild or severe psoriasis, relative 
risk is 1.29 and 3.1 respectively. In a 60-year-old patient, 
relative risk is 1.08 for mild psoriasis and 1.36 for severe 
psoriasis (Gelfand et al 2006). As such, the CV risk con-
ferred by severe psoriasis in young individuals may be 
comparable to what is seen with other well established risk 
factors such as diabetes mellitus.
It appears that patients with more diffuse skin involvement 
have a higher CV risk. In a large European cohort of patients 
with psoriasis, the frequency of other co-morbidities associ-
ated with increased CV risk (obesity, diabetes mellitus, heart 
failure and hypertension) was signiﬁ  cantly increased when 
compared to control subjects (Henseler and Christophers 
1995). This has been veriﬁ  ed by other studies (Shapiro et al 
2007). Patients with psoriasis also have altered homocysteine 
metabolism which may confer additional vascular risk 
(Malerba et al 2006). The risk of CV death has been reported 
as 50% higher in patients hospitalized with psoriasis compared 
with expected rates(Poikolainen et al 1999). A population-
based study performed in the UK showed that diabetes, 
hypertension, hyperlipidemia, obesity and smoking are 
strongly associated with severe psoriasis, when compared to 
mild psoriasis. However, whether these associations were just 
the effect of concomitant use of medications potentially linked 
to increased CV risk factors was not addressed. Psoriasis is 
also associated with changes in plasma lipids and lipoproteins 
(Ofﬁ  dani et al 1994; Seishima et al 1994; Uyanik et al 2002) 
which may play a role in the development of atherosclerotic 
vascular disease. Increased levels of autoantibodies to oxidized 
LDL have been reported in patients with psoriasis and may 
potentially play a role in vascular damage (Orem et al 1999; 
Sommer et al 2006). Furthermore, patients with psoriasis dis-
play elevated markers of inﬂ  ammatory responses, including 
C-reactive protein (Strober et al 2008). The strong association 
between psoriasis and obesity potentially makes the former an 
important healthcare issue that will likely require an update 
in its standard of care (Sterry et al 2007; Gisondi et al 2007). 
Overall, it is clear that metabolic syndrome prevalence is 
increased in patients with psoriasis and this could play an 
important role in heightened CVD development in this 
disease.
In addition to atherosclerotic CAD, patients with 
psoriasis appear to be at risk for other CV complications. 
Arrhythmias are more prevalent in psoriasis (Mastrolonardo 
2008). Left ventricular hypertrophy, diastolic dysfunction 
and valvular pathologies are also more common in this 
disease (Markuszeski et al 2007). An enhanced stress-
induced autonomic response and diminished pituitary 
adrenal activity have been reported in psoriasis, with higher 
adrenaline values but diminished cortisol and dehydroepi-
androsterone (DHEA) plasma values. This effect decreases 
with psolaren plus ultraviolet light A (PUVA) treatment 
(Schmid-Ott et al 1998).
Although psoriatic arthritis may also be associated with 
an excess prevalence of  CV risk factors, it remains uncertain 
whether higher rates of clinical CVD are independently 
associated with the disease itself (reviewed in Roman and 
Salmon 2007).
Even with a higher prevalence of proatherosclerotic 
metabolic comorbidities in psoriasis, this disease appears to 
be an independent risk factor for MI when controlling for 
major CV risk factors (Gelfand et al 2006). Therefore, the 
mechanisms contributing to accelerated atherosclerosis and 
overall CV risk in psoriasis are likely to be multifactorial: 
a) psoriasis and CVD may share common risk factors, such 
as tobacco use; b) a higher prevalence of traditional CV risk 
factors in psoriasis may likely increase CV risk (Cohen et al 
2008); c) intrinsic associated risks due to systemic inﬂ  amma-
tion and immune dysregulation may play a role in vascular 
damage in psoriasis. This possibility requires conﬁ  rmation 
with prospective studies and clearly requires a better under-
standing of how inﬂ  ammatory/immune-mediated responses 
could contribute to vascular damage in this disease.
In order to better understand the potential link of psoriasis 
with CVD, we will review some of the pathogenic mechanisms 
recently implicated in the development of psoriasis:
Pathophysiology of psoriasis 
and PsA
As no pathogen has been consistently identiﬁ  ed within 
psoriatic plaques, an autoimmune/pro-inﬂ  ammatory basis has 
been considered in psoriasis (Nickoloff et al 2007). Overall, 
psoriasis is characterized by augmented antigen-presenting 
cell (APC) activation and antigen (Ag) presentation, T-cell 
activation and Th1 cytokine production.Vascular Health and Risk Management 2008:4(6) 1231
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Genetic factors
The precise genetic loci that convey enhanced disease 
susceptibility in psoriasis remain to be deﬁ  ned. Psoriasis is 
associated with certain HLA-types (HLA-Cw6, HLA-B13, 
HLA-B17, HLA-Bw57, and HLA-DR4). People with HLA-
Cw6, for example, have a 10-fold higher risk of disease 
(Schon and Boehncke 2005). The primary locus appears to 
be located on the short arm of chromosome 6 (PSORS1) 
within the HLA complex, and appears to be in proximity 
to HLA-Cw6 (Gudjonsson et al 2006; Lesueur et al 2007). 
Environmental/epigenetic factors likely play a role in disease 
pathogenesis, as the concordance in monozygous twins is 
only 35%–56% (Duffy et al 1993).
Cytokines
Persistent T cell activation within psoriatic plaques resembles 
Th1 responses (Hueber and McInnes 2007). TNF-α is 
overexpressed in psoriatic lesions. NK-T cells and NK cells 
have also been implicated in the immunopathogenesis of 
psoriasis and psoriatic arthritis (Chan et al 2003; Gaspari 
2006). The T helper (Th) 17 cell, a novel T-cell subset, has 
been implicated in the pathogenesis of psoriasis and other 
autoimmune inﬂ  ammatory diseases (Blauvelt 2008; Haider 
et al 2008). IL-23 stimulates survival and proliferation of 
Th17 cells, acting as a key regulator for these diseases. In 
psoriasis, IL-23 is overproduced by dendritic cells (DCs) 
and keratinocytes, and this cytokine stimulates Th17 cells 
within dermis to make IL-17A and IL-22. The latter drives 
keratinocyte proliferation in psoriasis (Aggarwal et al 2003; 
Fitch et al 2007). The link between Th1 and Th17 responses 
in the promotion of CVD is the subject of active investigation 
(Cheng et al 2008, Wilensky and Hamamdzic, 2007).
Dendritic cells (DCs)
The interactions between DCs and T-cells, and associated 
downstream responses play essential roles in the formation 
of chronic psoriatic plaques (Jariwala 2007). Several abnor-
malities in DC subsets have been detected within psoriatic 
plaques. More recently, other DC subsets have been reported 
within psoriatic skin, including the TNF-α inducible nitric 
oxide synthases-expressing DCs and the plasmacytoid 
DCs (Komine et al 2007). The plasmacytoid DCs (pDCs) 
produce high levels of IFN-α and in animal models of 
psoriasis, injecting neutralizing antibodies against this 
molecule prevented the induction of psoriatic lesions after 
xenotransplantation (Nestle et al 2005). A role for IFN-α in 
triggering psoriasis is supported by the clinical observations 
that patients receiving IFN-α injections for different 
conditions may develop psoriasis or experience a ﬂ  are of 
psoriatic lesions (Descamps 2005; Gaal et al 2005; Yurci 
et al 2007). Interestingly, recent work in SLE has proposed 
a link between type I IFNs and abnormal vasculogenesis 
which may promote endothelial dysfunction and, potentially 
atherosclerosis (Denny et al 2007). Whether type I IFNs 
play any role in vascular damage in psoriasis remains to be 
determined.
Other APCs
Activated macrophages have been linked to the formation of 
psoriatic plaques (Neylon and Haight 1983; Wang et al 2006). 
It has been postulated that these cells may circulate from 
the oral cavity into the skin and trigger a Th1 type cellular 
immune reaction leading to the formation of psoriatic lesions. 
A direct role for macrophages in the contribution to cutaneous 
inﬂ  ammation was established by the local elimination of 
macrophages that led to disease resolution (Wang et al 2006) . 
The role of inﬂ  ammatory macrophages in vascular damage 
in psoriasis remains to be determined.
T regulatory cells (Tregs)
While Tregs have been identified in psoriatic lesions 
(Bovenschen et al 2006), they do not appear to function 
properly (Kagen et al 2006). Also, 1,25-dihydroxyvitamin D3, 
an effective therapeutic compound for psoriasis, promotes 
DC mediated induction of CD4 + Foxp3 + Treg cells (Penna 
et al 2005). Recent studies from several groups suggest 
that T regs may play a role in inhibiting the development 
and progression of atherosclerosis, adding a potential link 
between psoriasis and CAD (Gotsman et al 2007).
Infections
Microorganisms have been associated to the development 
of psoriasis. β-hemolytic streptococcal infections are linked 
to the development of guttate psoriasis and intercurrent 
infections have been associated to pustular psoriasis ﬂ  ares. 
Patients with HIV infection have a higher prevalence of 
psoriasis. However, whether microbial infections play a 
substantial pathogenic role in the majority of patients with 
psoriasis has not been demonstrated. Furthermore, whether an 
infectious agent is involved in vascular damage in psoriasis 
has not been investigated (Grifﬁ  ths and Barker 2007).
Overall, shared immunological abnormalities between 
psoriasis and atherosclerosis include APC and T cell activation, 
activation of NFκB and Toll-like receptor (TLR) expression, 
aberrant Tregs and abnormal cytokine responses. Furthermore, 
both diseases appear to have Th1/Th2 imbalances and increase Vascular Health and Risk Management 2008:4(6) 1232
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in CD40/CD40 L signaling interaction, upregulation of speciﬁ  c 
chemokines and adhesion molecules. Activated macrophages 
are clearly linked to the formation of atherosclerotic plaques 
involving oxidized forms of LDL. Migratory macrophages and 
TNF-α are linked to obesity-induced insulin resistance. Several 
cytokines that have been identiﬁ  ed as important mediators of 
psoriasis, such as IL-1, 4, 6, 8, 12, and TNF-α have also been 
identiﬁ  ed in the metabolic syndrome.
Other mechanisms that have been shown to potentially play 
a role in premature CVD in other inﬂ  ammatory conditions such 
as RA or SLE include cytotoxic T cells (Gerli et al 2004), pro-
inﬂ  ammatory cytokines (Branen et al 2004), aberrant vascular 
repair (Grisar et al 2005; Denny et al 2007) and potential genetic 
inﬂ  uences (reviewed in Kaplan 2006). The role of these factors 
on the development of CVD in psoriasis has not been studied.
Role of pharmacologic interventions 
in CV risk in psoriasis
Several drugs used to treat psoriasis and/or psoriatic arthritis 
also have effects on the endothelium and, potentially, on the 
incidence of vascular complications. Extrapolating from what 
we know about the role of certain immunosuppressants and 
CV morbidity in RA, there is still considerable uncertainty 
on the role that certain drugs used to treat psoriasis may play 
in the health of the endothelium (reviewed in Kaplan 2006). 
This is in part due to the notion that medications used to treat 
inﬂ  ammatory conditions may have dual effects on risk for 
CV morbidity. For example, steroids might decrease the risk 
for CV complications in RA by decreasing inﬂ  ammation, but 
they might increase it by promoting proatherosclerotic lipid 
proﬁ  les. RA patients exposed to glucocorticoids appear to 
have an increased incidence of carotid plaque and arterial 
incompressibility (del Rincon et al 2004). The link between 
steroids and CVD in SLE is unclear and recent studies suggest 
a protective effect (Roman et al 2003).
Methotrexate can promote hyperhomocysteinemia (which is 
corrected by folic acid addition) and cause endothelial damage 
(Merkle et al 2000; Dierkes and Westphal 2005). However, 
MTX reduced the incidence of vascular disease in veterans with 
psoriasis and RA (Choi et al 2002; Prodanovich et al 2005). Low 
to moderate cumulative doses appeared to be more beneﬁ  cial 
than higher doses. In addition, a combination of methotrexate and 
folic acid led to a further reduction in the incidence of CVD.
The effects of  TNF-α blockers on CVD are also complex 
because these drugs may promote heart failure and decrease 
heart compliance while controlling inflammation and 
decreasing risk for plaque formation. Inﬂ  iximab appears to 
improve endothelial function in RA after 3 months of therapy 
(Hurlimann et al 2002). A Scandinavian study suggested 
that the risk for developing ﬁ  rst CV events in RA is lower in 
patients treated with TNF blockers (Jacobsson et al 2005). 
While this study did not control for most of the traditional 
and nontraditional risk factors, these results indicate that 
prospective, long-term, longitudinal studies are required to 
evaluate the precise role of anti-TNF therapy in atherosclerosis 
prevention in speciﬁ  c conditions such as psoriasis.
Anti-TNF therapy can also improve other risk factors for 
accelerated atherosclerosis, including promoting a decrease in 
insulin resistance, CRP and IL-6, and an increase in high-density 
lipoprotein (Kiortsis et al 2005; Popa et al 2005). Of note, the 
beneﬁ  cial effects of anti-TNF agents on endothelial function 
do not appear to be sustained and are not seen in diabetic 
patients treated with etanercept (Gonzalez-Juanatey et al 2004; 
Dominguez et al 2005). In fact, while an initial improvement in 
RA endothelial function was observed with inﬂ  iximab, values 
returned to baseline 4 weeks after the infusion in patients followed 
for 1 year (Gonzalez-Juanatey et al 2004). As a cautionary note, 
while inﬂ  iximab induces a transient increase in ﬂ  ow-mediated 
dilatation (FMD), it can also induce vasoconstriction, increases 
in wall shear stress, and deleterious effects on high-density 
lipoprotein (Irace et al 2004). It is possible that different TNF 
antagonists show differential effects on endothelial and smooth 
muscle cells and on vascular function. Further, animal studies sug-
gest a negative inﬂ  uence of TNF-α inhibitors on collateral artery 
growth (Grundmann et al 2005). This observation deserves further 
investigation into the potential role of TNF blockers in decreasing 
mechanisms of cardiac perfusion in individuals with impaired 
coronary circulation. Interestingly, in psoriasis, etanercept has 
been shown to improve insulin sensitivity (Marra et al 2007).
Regarding anti-inﬂ  ammatory therapies, recent studies 
indicate that NSAIDs might have a role in suppressing MI 
risk in RA and other inﬂ  ammatory conditions and that, 
ideally, abrupt discontinuation of NSAIDS in these patient 
populations should be avoided (Fischer et al 2004).
Finally, it appears that statins can mediate modest but 
clinically apparent anti-inﬂ  ammatory effects in inﬂ  ammatory 
arthritis (McCarey et al 2004). Atorvastatin and simvastatin 
promoted signiﬁ  cant improvements in markers of CV risk. 
Recent studies have proposed a beneﬁ  cial effect of statins in 
psoriasis activity and their role in CVD prevention in this disease 
deserves further investigation (Shirinsky and Shirinsky 2007).
Conclusion
The pathogenic mechanisms involved in accelerated 
CV complications in psoriasis and PsA are complex and 
multifactorial. Overall, studies published over the past Vascular Health and Risk Management 2008:4(6) 1233
Cardiometabolic risk in psoriasis
decade have conﬁ  rmed a higher risk for CV complications 
in psoriasis, and indicate that aggressive prevention and 
treatment of risk factors are likely to be of extreme impor-
tance in this patient population. Given what we know about 
the development of metabolic syndrome (Table 1) and CV 
risk factors in other systemic inﬂ  ammatory diseases, these 
strategies will likely include appropriate control of the 
inﬂ  ammatory abnormalities and metabolic changes seen in 
psoriasis. Established and potential preventive strategies are 
summarized in Table 2. More studies are required to assess 
the exact role that anti-TNF therapies and other biologicals 
might have in CVD prevention in psoriasis. It is clear that 
there is a great need for heightened awareness of the increased 
risk for vascular damage in patients with psoriasis.
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